Back to Search Start Over

Hydralazine represses Fpn ubiquitination to rescue injured neurons via competitive binding to UBA52.

Authors :
Li, Shengyou
Gao, Xue
Zheng, Yi
Yang, Yujie
Gao, Jianbo
Geng, Dan
Guo, Lingli
Ma, Teng
Hao, Yiming
Wei, Bin
Huang, Liangliang
Wei, Yitao
Xia, Bing
Luo, Zhuojing
Huang, Jinghui
Source :
Journal of Pharmaceutical Analysis; Jan2024, Vol. 14 Issue 1, p86-99, 14p
Publication Year :
2024

Abstract

A major impedance to neuronal regeneration after peripheral nerve injury (PNI) is the activation of various programmed cell death mechanisms in the dorsal root ganglion. Ferroptosis is a form of programmed cell death distinguished by imbalance in iron and thiol metabolism, leading to lethal lipid peroxidation. However, the molecular mechanisms of ferroptosis in the context of PNI and nerve regeneration remain unclear. Ferroportin (Fpn), the only known mammalian nonheme iron export protein, plays a pivotal part in inhibiting ferroptosis by maintaining intracellular iron homeostasis. Here, we explored in vitro and in vivo the involvement of Fpn in neuronal ferroptosis. We first delineated that reactive oxygen species at the injury site induces neuronal ferroptosis by increasing intracellular iron via accelerated UBA52-driven ubiquitination and degradation of Fpn, and stimulation of lipid peroxidation. Early administration of the potent arterial vasodilator, hydralazine (HYD), decreases the ubiquitination of Fpn after PNI by binding to UBA52, leading to suppression of neuronal cell death and significant acceleration of axon regeneration and motor function recovery. HYD targeting of ferroptosis is a promising strategy for clinical management of PNI. [Display omitted] • ROS induces neuronal ferroptosis via accelerated UBA52-driven ubiquitination of Fpn. • DRGs undergo cell death within 24 h after peripheral nerve injury. • HYD inhibits Fpn degradation in DRGs by suppressing UBA52 binding to Fpn. • Immediate HYD treatment produced better outcomes than delayed HYD treatment. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20951779
Volume :
14
Issue :
1
Database :
Supplemental Index
Journal :
Journal of Pharmaceutical Analysis
Publication Type :
Academic Journal
Accession number :
175165057
Full Text :
https://doi.org/10.1016/j.jpha.2023.08.006